The present invention relates to compounds of pharmaceutical interest. More particularly, it relates to compounds of formula (I), to processes for obtaining thereof, to the intermediates of their synthesis and processes for obtaining the latter. The compounds of formula (I) have a certain affinity with the vitamin D receptor, they are active in a similar order to 1,25-dihydroxyvitamin D.sub.3 (1,25D), with the advantage of producing less or no hypercalcemia.

A catalyst is provided. The catalyst includes a carrier and a metal. The carrier is represented by a formula: M.sub.xAl.sub.(1-x)O.sub.(3-x)/2, where M is an alkaline earth metal, and x is between 0.09 and 0.24. The metal is loaded on the carrier. A method for manufacturing the catalyst is also provided.

A catalyst is provided. The catalyst includes a carrier and a metal. The carrier is represented by a formula: M.sub.xAl.sub.(1-x)O.sub.(3-x)/2, where M is an alkaline earth metal, and x is between 0.09 and 0.24. The metal is loaded on the carrier. A method for manufacturing the catalyst is also provided.

Disclosed are 2-methylene analogs of vitamin D.sub.3 and related compounds, their biological activities, and various pharmaceutical uses for these analogs. Particularly disclosed are 1-hydroxy-2-methylene-vitamin D.sub.3, (20S)-1-hydroxy-2-methylene-vitamin D.sub.3, and (5E)-1,25-dihydroxy-2-methylene-vitamin D.sub.3, their biological activities, and various pharmaceutical uses for these compounds including methods of treating and/or preventing bone diseases and disorders.

Disclosed are 2-methylene analogs of vitamin D.sub.3 and related compounds, their biological activities, and various pharmaceutical uses for these analogs. Particularly disclosed are 1-hydroxy-2-methylene-vitamin D.sub.3, (20S)-1-hydroxy-2-methylene-vitamin D.sub.3, and (5E)-1,25-dihydroxy-2-methylene-vitamin D.sub.3, their biological activities, and various pharmaceutical uses for these compounds including methods of treating and/or preventing bone diseases and disorders.

A catalyst is provided. The catalyst includes a carrier and a metal Pd. The carrier is represented by a formula: M.sub.xAl.sub.(1x)O.sub.(3x)/2, where M is an alkaline earth metal, and x is between 0.09 and 0.24. The metal Pd is loaded on the carrier. A method for manufacturing the catalyst and a method for manufacturing a hydrogenated bisphenol A or derivatives thereof using the catalyst are also provided.

A catalyst is provided. The catalyst includes a carrier and a metal Pd. The carrier is represented by a formula: M.sub.xAl.sub.(1x)O.sub.(3x)/2, where M is an alkaline earth metal, and x is between 0.09 and 0.24. The metal Pd is loaded on the carrier. A method for manufacturing the catalyst and a method for manufacturing a hydrogenated bisphenol A or derivatives thereof using the catalyst are also provided.

Methods for the synthesis of a tricyclic-prostaglandin D.sub.2 metabolite methyl ester or a pharmaceutically acceptable salt thereof.

Methods for the synthesis of a tricyclic-prostaglandin D.sub.2 metabolite methyl ester or a pharmaceutically acceptable salt thereof.